In this study, the authors showed that metformin activates the LKB1/AMPK pathway in AML and reduces tumor size in a mice xenograft model through the repression of mTOR-dependent oncogenic mRNA translation (c-MYC, CYCLIN-D, BCL-XL). Here, PRKAB1 is linked to neoplasm.